78 related articles for article (PubMed ID: 7562044)
1. Predicting malignancy grade with PET in non-Hodgkin's lymphoma.
Rodriguez M; Rehn S; Ahlström H; Sundström C; Glimelius B
J Nucl Med; 1995 Oct; 36(10):1790-6. PubMed ID: 7562044
[TBL] [Abstract][Full Text] [Related]
2. Computed tomography, magnetic resonance imaging and positron emission tomography in non-Hodgkin's lymphoma.
Rodriguez M
Acta Radiol Suppl; 1998; 417():1-36. PubMed ID: 9645167
[TBL] [Abstract][Full Text] [Related]
3. Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study.
Leskinen-Kallio S; Ruotsalainen U; Någren K; Teräs M; Joensuu H
J Nucl Med; 1991 Jun; 32(6):1211-8. PubMed ID: 2045935
[TBL] [Abstract][Full Text] [Related]
4. Use of carbon-11 methionine positron emission tomography to assess malignancy grade and predict survival in patients with lymphomas.
Nuutinen J; Leskinen S; Lindholm P; Söderström KO; Någren K; Huhtala S; Minn H
Eur J Nucl Med; 1998 Jul; 25(7):729-35. PubMed ID: 9662595
[TBL] [Abstract][Full Text] [Related]
5. Comparison of fluorine-18-fluorodeoxyglucose and carbon-11-methionine in head and neck cancer.
Lindholm P; Leskinen-Kallio S; Minn H; Bergman J; Haaparanta M; Lehikoinen P; Någren K; Ruotsalainen U; Teräs M; Joensuu H
J Nucl Med; 1993 Oct; 34(10):1711-6. PubMed ID: 8410288
[TBL] [Abstract][Full Text] [Related]
6. The use of PET-18FDG imaging in the clinical evaluation of head and neck lymphoma.
Walsh RM; Wong WL; Chevretton EB; Beaney RP
Clin Oncol (R Coll Radiol); 1996; 8(1):51-4. PubMed ID: 8688363
[TBL] [Abstract][Full Text] [Related]
7. Increased glucose metabolism in untreated non-Hodgkin's lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose.
Lapela M; Leskinen S; Minn HR; Lindholm P; Klemi PJ; Söderström KO; Bergman J; Haaparanta M; Ruotsalainen U; Solin O; Joensuu H
Blood; 1995 Nov; 86(9):3522-7. PubMed ID: 7579459
[TBL] [Abstract][Full Text] [Related]
8. Clinical positron emission tomography for brain tumors: comparison of fludeoxyglucose F 18 and L-methyl-11C-methionine.
Ogawa T; Inugami A; Hatazawa J; Kanno I; Murakami M; Yasui N; Mineura K; Uemura K
AJNR Am J Neuroradiol; 1996 Feb; 17(2):345-53. PubMed ID: 8938309
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of PET with 18F-fluorodeoxyglucose and L-methyl-11C-methionine for diagnosis of recurrent brain tumor and radiation injury.
Ogawa T; Kanno I; Shishido F; Inugami A; Higano S; Fujita H; Murakami M; Uemura K; Yasui N; Mineura K
Acta Radiol; 1991 May; 32(3):197-202. PubMed ID: 2064862
[TBL] [Abstract][Full Text] [Related]
10. Positron emission tomography in non-Hodgkin's lymphoma (NHL): relationship between tracer uptake and pathological findings, including preliminary experience in the staging of low-grade NHL.
Jerusalem GH; Beguin YP
Clin Lymphoma; 2002 Jun; 3(1):56-61. PubMed ID: 12141957
[TBL] [Abstract][Full Text] [Related]
11. [18FDG PET in the management of malignant lymphoma].
Cui RX; Zhou Q
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2003 Dec; 25(6):645-9. PubMed ID: 14714303
[TBL] [Abstract][Full Text] [Related]
12. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography.
Martiat P; Ferrant A; Labar D; Cogneau M; Bol A; Michel C; Michaux JL; Sokal G
J Nucl Med; 1988 Oct; 29(10):1633-7. PubMed ID: 3262725
[TBL] [Abstract][Full Text] [Related]
13. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma.
Jerusalem G; Beguin Y; Fassotte MF; Najjar F; Paulus P; Rigo P; Fillet G
Haematologica; 2000 Jun; 85(6):613-8. PubMed ID: 10870118
[TBL] [Abstract][Full Text] [Related]
14. Investigating the existence of quantum metabolic values in non-Hodgkin's lymphoma by 2-deoxy-2-[F-18]fluoro-D-glucose positron emission tomography.
Wong CY; Thie J; Parling-Lynch KJ; Zakalik D; Wong RH; Gaskill M; Margolis JH; Hill J; Sukari A; Chundru S; Fink-Bennett D; Nagle C
Mol Imaging Biol; 2007; 9(1):43-9. PubMed ID: 17176979
[TBL] [Abstract][Full Text] [Related]
15. Simplified measurement of deoxyglucose utilization rate.
Hunter GJ; Hamberg LM; Alpert NM; Choi NC; Fischman AJ
J Nucl Med; 1996 Jun; 37(6):950-5. PubMed ID: 8683318
[TBL] [Abstract][Full Text] [Related]
16. Does partial volume corrected maximum SUV based on count recovery coefficient in 3D-PET/CT correlate with clinical aggressiveness of non-Hodgkin's lymphoma?
Tsujikawa T; Otsuka H; Morita N; Saegusa H; Kobayashi M; Okazawa H; Nishitani H
Ann Nucl Med; 2008 Jan; 22(1):23-30. PubMed ID: 18250984
[TBL] [Abstract][Full Text] [Related]
17. Positron emission tomography in the diagnosis and staging of urinary bladder cancer.
Ahlström H; Malmström PU; Letocha H; Andersson J; Långström B; Nilsson S
Acta Radiol; 1996 Mar; 37(2):180-5. PubMed ID: 8600958
[TBL] [Abstract][Full Text] [Related]
18. The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis.
Okada J; Yoshikawa K; Imazeki K; Minoshima S; Uno K; Itami J; Kuyama J; Maruno H; Arimizu N
J Nucl Med; 1991 Apr; 32(4):686-91. PubMed ID: 2013808
[TBL] [Abstract][Full Text] [Related]
19. PET studies with L-[1-11C]tyrosine, L-[methyl-11C]methionine and 18F-fluorodeoxyglucose in prolactinomas in relation to bromocryptine treatment.
Daemen BJ; Zwertbroek R; Elsinga PH; Paans AM; Doorenbos H; Vaalburg W
Eur J Nucl Med; 1991; 18(7):453-60. PubMed ID: 1915472
[TBL] [Abstract][Full Text] [Related]
20. Whole-body diffusion-weighted MRI and (18)F-FDG PET/CT can discriminate between different lymphoma subtypes.
Mosavi F; Wassberg C; Selling J; Molin D; Ahlström H
Clin Radiol; 2015 Nov; 70(11):1229-36. PubMed ID: 26208992
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
